The global car-t cell therapy market will reach 8.5 billion US dollars by 2028

Source: bosengi cell therapy 2017-2-16 according to coherentmarket insights analysis, the global car-t cell therapy market is expected to reach 8.5 billion US dollars in 2028 The key factor that has led to this huge market demand is the high success rate of clinical treatment based on genetic engineering technology and the increasing incidence rate of cancer, which jointly drive the global demand for CAR-T cell therapy products Recently, car-t cell therapy has become a new pillar of cancer treatment, creating a high market potential for companies engaged in product development and promotion At present, Novartis international, Juno therapeutics and kitepharma are the three giants of car-t cell therapy market Their clinical research shows that the remission rate of refractory and relapsed B-ALL and DLBCL patients has reached an unprecedented high These companies are investing heavily in research and development to speed up the clinical process Novartis invested about $9 billion in research and development, most of which was allocated to oncology and the development of car-t cell products In the past two years, the new car-t cell immunotherapy has attracted a lot of investment The driving force for the growth of car-t cell therapy market mainly comes from the increasing demand for cancer efficient treatment mode, and tackling cancer has been the focus of the medical and health industry for many years Car-t cell therapy can kill tumor by genetically modified immune cells, which has become a life-saving drug for many patients with lymphoma and leukemia However, although the market prospect of car-t cell therapy is highly optimistic, the participants in car-t market need to solve the bottleneck problems of capacity and scale expansion, so as to generate higher profits For example, Novartis and kit have begun to develop a roadmap for their large-scale industrialization Market analysis: it is expected that North America will be the mainstream market of car-t cell therapy in the future The region is expected to account for 58.3% of the total industry share by 2018 In 2015, leukemia, lymphoma and myeloma accounted for 9.4% of the 1.6 million newly diagnosed cancer patients in North America About 55000 people die of leukemia, lymphoma and myeloma every year in the United States Car-t cell therapy has been considered to solve the problem of blood tumor It is expected that by 2020, with the adoption of this new treatment, the death rate will drop dramatically Europe is expected to become the second largest market for car-t therapy However, although the region is expected to create profitable market opportunities, clinical trials in different specific countries in Europe are expected to be a cumbersome process, which is a key challenge for car-t's growth prospects in the region CD19 based car-t therapy is expected to dominate the global car-t cell therapy market in the future Cd19-car-t products are expected to reach a billion dollar milestone in 2023 Many companies are using cd19-car-t to treat leukemia, while car-t for other antigens is also expected to create significant revenue opportunities for solid tumor treatment Currently, Novartis International AG and kitepharma are expected to be approved to launch their products in 2017 Juno therapeutics is expected to commercialize its products by 2018 In addition to these companies, companies such as bellicum pharmaceutical, celgene and cellectis are also engaged in relevant research and development and clinical trials, and devote their efforts to shorten the time to market of products, so as to seize this huge market opportunity in the next 10 years Editor's note: the number of new cancer patients in China is over 4 million every year, with nearly 3 million deaths The incidence rate of lymphoma ranks 10 in the list of cancer, while the mortality rate of lymphoma and leukemia is the top 10 of cancer deaths Therefore, the largest car-t therapy market will appear in China in the future.)